Regulatory Network in Protein Phosphorylation
[Home] [About] [Browse Kinome] [Phosphorylation Prediction] [Expression Analysis] [Statistics] [Help] Version 1.0

[Back to Kinase CK2a1]
Substrate: STMN1

Description: Stathmin (Phosphoprotein p19) (pp19) (Oncoprotein 18) (Op18)(Leukemia-associated phosphoprotein p18) (pp17) (Prosolin)(Metablastin) (Protein Pr22).

Synonyms: LAP18, OP18

Ensembl ID: ENSG00000117632

UniprotKB/SwissProt: STMN1_HUMAN (P16949)

Function: Involved in the regulation of the microtubule (MT) filament system by destabilizing microtubules. Prevents assembly and promotes disassembly of microtubules. Phosphorylation at Ser- 16 may be required for axon formation during neurogenesis. Involved in the control of the learned and innate fear (By similarity).

Other Modifications: View all modification sites in dbPTM

Protein Subcellular Localization: Cytoplasm.
Protein Domain and Phosphorylation Sites:

The phosphorylated sites of STMN1

No.SubstrateUniProtKB IDPositionPhosphoPeptideSolvent AccessibilityCatalytic kinaseSourceComputational Annotation of Catalytic KinaseInteracting PartnersExpression Analysis
1STMN1STMN1_HUMANS16LEKRA S GQAFE 35.16% Swiss-Prot 55.0 View   
2STMN1STMN1_HUMANS16LEKRA S GQAFE 35.16%CK2a1-rs HPRD:01047(in vitro;in vivo)  ViewAnalyzing
3STMN1STMN1_HUMANS16LEKRA S GQAFE 35.16%PKACa HPRD:01047(in vivo)  ViewAnalyzing
4STMN1STMN1_HUMANS16LEKRA S GQAFE 35.16%PAK1 Phospho.ELM 7.0  ViewAnalyzing
5STMN1STMN1_HUMANS16LEKRA S GQAFE 35.16%PKACa HPRD:01047(in vitro;in vivo)  ViewAnalyzing
6STMN1STMN1_HUMANS16LEKRA S GQAFE 35.16%CK2a1 HPRD:01047(in vitro;in vivo)  ViewAnalyzing
7STMN1STMN1_HUMANS25FELIL S PRSKE 15.98%CDC2 HPRD:01047(in vivo)  ViewAnalyzing
8STMN1STMN1_HUMANS25FELIL S PRSKE 15.98%CDC2 HPRD:01047(in vivo)  ViewAnalyzing
9STMN1STMN1_HUMANS25FELIL S PRSKE 15.98%Erk1 HPRD:01047(in vivo)  ViewAnalyzing
10STMN1STMN1_HUMANS25FELIL S PRSKE 15.98%p38d(MAPK13) Phospho.ELM 7.0 ViewAnalyzing
11STMN1STMN1_HUMANS25FELIL S PRSKE 15.98%PKCb(PKC beta) Phospho.ELM 7.0 ViewAnalyzing
12STMN1STMN1_HUMANS25FELIL S PRSKE 15.98%MAPK_group Phospho.ELM 7.0 ViewAnalyzing
13STMN1STMN1_HUMANS25FELIL S PRSKE 15.98%CDC2 Swiss-Prot 55.0   ViewAnalyzing
14STMN1STMN1_HUMANS25FELIL S PRSKE 15.98%MAPK_group Swiss-Prot 55.0  ViewAnalyzing
15STMN1STMN1_HUMANS28ILSPR S KESVP 44.13% Swiss-Prot 55.0 View   
16STMN1STMN1_HUMANS38PEFPL S PPKKK 39.12%CDK_group Phospho.ELM 7.0 ViewAnalyzing
17STMN1STMN1_HUMANS38PEFPL S PPKKK 39.12%p38d(MAPK13) Phospho.ELM 7.0 ViewAnalyzing
18STMN1STMN1_HUMANS38PEFPL S PPKKK 39.12%PKCb(PKC beta) Phospho.ELM 7.0 ViewAnalyzing
19STMN1STMN1_HUMANS38PEFPL S PPKKK 39.12%CDC2 HPRD:01047(in vivo)  ViewAnalyzing
20STMN1STMN1_HUMANS38PEFPL S PPKKK 39.12%CDC2 Swiss-Prot 55.0   ViewAnalyzing
21STMN1STMN1_HUMANS38PEFPL S PPKKK 39.12%CDC2 HPRD:01047(in vivo)  ViewAnalyzing
22STMN1STMN1_HUMANS46KKKDL S LEEIQ 43.82% Swiss-Prot 55.0 (Similarity)View   
23STMN1STMN1_HUMANS63EERRK S HEAEV 25.42%PKA_group Swiss-Prot 55.0  ViewAnalyzing
24STMN1STMN1_HUMANS63EERRK S HEAEV 25.42%PKA_group Phospho.ELM 7.0 ViewAnalyzing
25STMN1STMN1_HUMANS63EERRK S HEAEV 25.42%PKACa HPRD:01047(in vitro;in vivo)  ViewAnalyzing
26STMN1STMN1_HUMANS63EERRK S HEAEV 25.42%CK2a1-rs HPRD:01047(in vitro;in vivo)  ViewAnalyzing
27STMN1STMN1_HUMANS63EERRK S HEAEV 25.42%CK2a1 HPRD:01047(in vitro;in vivo)  ViewAnalyzing
28STMN1STMN1_HUMANT146DPADE T EAD 36.70% Swiss-Prot 55.0 View